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Abstract
Blood handling devices such as left ventricular assist devices and total artificial hearts 
offer life-saving treatments for patients suffering from severe heart failure. Current 
devices have clinically proven that heart assist pumps are a safe and effective therapy, 
and indeed in many cases they are the only available method of treatment. However, 
current devices cause side effects including stroke, bleeding, infection, and thrombo-
sis, preventing the technology from reaching its full potential. If the side effects could 
be reduced, then more patients could benefit from these devices. The complications are 
related to damage to blood cells and proteins as a result of contact with foreign materials 
and mechanical stress. There is a need for better devices with minimal blood impact to 
enable more patients to be safely treated; better tools, especially flow cytometry, could 
support the device development life cycle. In this chapter we review the clinical, in vivo, 
and in vitro flow cytometry data available for ventricular assist devices, conduct a gap 
analysis, and identify areas of future possibilities for device developers to establish new 
flow cytometry-based methodologies.
Keywords: multidimensional flow cytometry, translational research, ventricular assist, 
microparticles, multispecies
1. Introduction
Blood handling devices such as left ventricular assist devices and total artificial hearts offer 
life-saving treatments for patients suffering from severe heart failure. Current devices have 
clinically proven that heart assist pumps are a safe and effective therapy, and indeed in many 
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cases they are the only available method of treatment. However, current devices cause side 
effects including stroke, bleeding, infection, and thrombosis, preventing the technology from 
reaching its full potential [1]. If the side effects could be reduced, then more patients could 
benefit from these devices. The complications are related to damage to blood cells and circu-
lating proteins as a result of contact with foreign materials and mechanical stress. There is a 
need for better devices with minimal negative effect on blood to enable more patients to be 
treated safely; better tools, especially flow cytometry, could support the device development 
life cycle.
The use of multidimensional flow cytometry during pre-clinical development of blood 
handling devices offers a powerful tool to monitor changes to erythrocytes, leukocytes, and 
platelets, as well as circulating mediators such as von Willebrand factor. A key challenge 
is the need to study these in cows, sheep and pigs which are used for pre-clinical stud-
ies. This is associated with markedly reduced reagent options compared to studies using 
human blood. While there are some species-specific antibodies suitable for flow cytometry, 
the preferential use of cross-reactive reagents and species non-specific tools enables mul-
ticolor panels to be developed that can be used with blood from multiple species. Such an 
approach also allows for comparisons at all stages of device development and implemen-
tation: in vitro, in vivo pre-clinical, and ex vivo clinical settings. Flow cytometry methods 
could also support personalised treatment strategies to potentially predict patients at risk 
of complications [2]. This could be prior to or following implantation of a device. Here, 
we will provide an overview of the development of flow cytometry tools to address this 
need including a review of work performed to date, as well as future possibilities for this 
technology platform.
2. Current use of flow cytometry for ventricular assist and total 
artificial heart research
The majority of the flow cytometry research performed in the area of blood-handling medical 
devices is to further the understanding of the complications that arise upon ventricular assist 
device implantation into heart failure patients. Since the aim of using flow cytometry during 
in vitro and
in vivo device testing is to maximise its haemocompatibility and minimise complications, it 
makes sense to start this review with the clinical data. The gaps in in vitro and in vivo research 
and development will then become evident and lay the foundation for the future possibilities 
for device developers.
2.1. Clinical flow cytometry data from ventricular assist devices
Flow cytometry has been used to analyse all major cellular components of the blood—i.e. 
erythrocytes, leukocytes, and thrombocytes—in VAD-patients.
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2.1.1. Erythrocytes
Sansone et al. were the first group to use flow cytometry in the clinic to evidence VAD-related 
damage to erythrocytes, in addition to the standard method of measuring plasma free haemo-
globin [3]. Patients implanted with continuous flow (CF) VADs (HVAD, HeartWare), showed 
significantly greater levels of CD235+ erythrocyte MPs compared to controls (both age-matched 
healthy and patients with stable coronary artery disease, CAD). Their erythrocyte counts were not 
described, but the VAD-patients had significantly greater levels of free haemoglobin compared 
to controls. Increased levels of erythrocyte MPs have been found in patients suffering sickle cell 
disease and β-thalassemia major, which are diseases also characterised by haemolysis [3].
2.1.2. Leukocytes
From a flow cytometry perspective leukocytes have received more attention than erythro-
cytes. VAD-related leukocyte damage has been demonstrated using flow cytometry in all 
major leukocyte subsets. Using the pan-leukocyte marker CD45, leukocyte microparticles 
(CD45+) were shown to be elevated in CF VAD patients compared to healthy and CAD con-
trols [3]. This is indicative of overall leukocyte destruction and is supported by Woolley 
et al. who observed decreased total leukocyte counts in CF VAD patients [4]. In the same 
study, CD15+ neutrophils were found to become activated as measured by an increase in 
MAC-1 (CD11b) expression. The level of activated neutrophils was dependent on pump type: 
HeartMate II causing greater levels than HVAD and PVAD [4]. Neutrophil activation status 
might also influences the patient’s susceptibility to infection as more HeartMate II patients 
than HVAD patients suffered from infection. The PVAD has a larger driveline exit area which 
contributes to infection rates, hence it cannot be directly compared to the other two pumps 
[5]. In vitro, neutrophils release CD11b+ MPs during activation [6–8] and could therefore be the 
parental cell type for the CD11b+ MPs that are elevated significantly in VAD-patients (mainly 
HeartMate II patients) compared to healthy controls [9].
Monocytes also become activated in VAD-patients with the expression of tissue factor 
(TF) increased significantly within the first month of pulsatile Novacor or HeartMate XVE 
support versus healthy controls [10, 11]. TF is a key element of the extrinsic coagulation 
cascade, and it is able to trigger coagulation, even with endothelial integrity virtually pre-
served. The major source of TF in blood is monocytes, and the expression is upregulated 
by for example lipopolysaccharides (LPS) [12]. As summarised by Angelillo-Scherrer: 
volunteers exposed to endotoxin, patients with meningococcal sepsis, and primates with 
Ebola fever, all show increased levels of CD14+/TF+ MPs, indicating a potential role for 
these MPs in disseminated intravascular coagulation associated with severe infections [12]. 
As driveline infections is a common problem in VAD-patients, there is a possibility that 
CD14+ monocytes expressing TF and/or CD14+TF+ MPs, could be a thrombosis risk marker 
in patients with ongoing infection.
Lymphocytes are affected by both pulsatile and CF-VADs [13–15]. A general lymphope-
nia occurred in patients, implanted with the early pulsatile HeartMate XVE [14]. This was 
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accompanied by a significant reduction in the mean CD4/CD8 T cell ratios, and in the mean 
number of circulating CD4 T cells. The CD4/CD8 T cell ratio decreased rapidly within the first 
month and remained low at the 2 month follow-up assessment [14]. The decline in CD4 T cells 
was attributed to a heightened susceptibility to apoptosis as measured by surface expression 
of phosphatidylserine through annexin V binding [14]. These results were confirmed in a 
group of patients implanted with either the pulsatile HeartMate XVE or the Novacor, where 
the mean number of circulating CD4 T cells was significantly lower compared to medically 
managed heart failure patient controls. While the levels of CD8 T cells remained unaffected 
[15], both CD4 and CD8 T cells had increased CD95(Fas) expression and annexin V bind-
ing versus controls, indicating apoptosis. Furthermore, the LVAD-patients had a significantly 
greater risk of developing candidal infection compared to the controls or other patients under-
going cardiac surgery. Altogether, this suggests that the pulsatile LVADs cause T-cell defects, 
most notably CD4 T-cell defects, and that some of these defects are measurable through flow 
cytometry [14, 15]. How this translates to an effect on the function of T cells remains to be 
determined.
Patients with CF-VADs also have changes in their T cell levels. However, contrary to pulsa-
tile LVAD-patients, those implanted with CF-VADs (specific device not published) and who 
suffered from infection had significantly higher levels of CD4+/CD25+ Tregs and increased 
lymphocyte reactive oxygen species (ROS) compared to VAD-patients without infection [13]. 
Whether these differences between pulsatile and CF VADs relates to pulsatility would be an 
interesting topic for further studies.
As far as we are aware, circulating B cells and NK cells have not been studied by flow cytom-
etry in LVAD-patients. Nor have other minor populations such as dendritic cells or innate 
lymphoid cells. There are some data of the effect of VADs on B cells from in vitro studies 
(Schuster 2002) and these are discussed below.
2.1.3. Platelets
Platelets have been studied on their own and in microaggregates with leukocytes. Wilhelm 
et al. found that platelets were activated in patients with pulsatile VADs (Novacor and 
HeartMate XVE) compared to healthy controls [11]. This was measured as significantly 
increased CD62P expression. However, Dewald showed that increased platelet activation 
might not be due to the VAD as platelets in heart failure patients are already activated prior 
to implantation. This was shown using antibodies against CD62P, CD63, and antithrombos-
pondin [16]. Similarly, Matsubayashi showed that CD62P and CD63 expression are elevated 
on platelets in Novacor-patients compared to healthy controls, but preoperative values were 
already high with no clear increase or decrease during implantation [17]. Further highlight-
ing the impact of heart failure rather than VAD use on platelet activation in vivo granulo-
cyte-platelet (CD15+/CD42b+) and monocyte-platelet (CD14+/CD42b+) aggregates were also 
increased significantly in the pulsatile VAD patients versus healthy controls before and after 
VAD implantation [11].
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Platelet MPs also have been detected using flow cytometry in CF-LVAD patients [3, 9]. In 
2010, Diehl P et al. showed that LVAD-patients, the majority of whom were implanted with 
the CF-LVAD HeartMate II, had significantly increased levels of CD31+/CD61+ platelet MPs 
compared to healthy controls [9]. Five years later, Sansone et al. showed that CD31+/CD41+ 
platelet MPs were elevated in patients 3 months post-implantation of a HVAD (a CF-LVAD) 
in comparison to both age-matched healthy controls and patients suffering from coronary 
artery disease (CAD) [3]. Hence, although the HeartMate II and the HVAD differ drastically 
in design, both were associated with platelet microparticle formation.
The focus has been on platelet activation and platelet MPs but these have so far not shown a 
utility as predictors of adverse events or stratifiers. However, there are other platelet param-
eters, all measurable by flow cytometry, that have potential as patient risk stratifiers, or even 
predictors, for bleeding complications in patients with CF-VADs [18–20]. These include sig-
nificantly greater levels of reactive oxygen species, mitochondrial damage, surface phos-
phatidylserine (PS) expression/apoptosis, and significantly decreased expression of α2bβ3 
on the platelet surface, in bleeders compared to non-bleeders [18–20]. The CF-VADs stud-
ied included the HeartMate II, Jarvik 2000, and the HVAD and no differences were found 
between the devices.
2.1.4. Endothelial cells and microparticles of unknown origin
CD62E+ endothelial cell microparticles (EMPs) are increased in VAD-patients compared to 
healthy controls [3, 9] and CAD patients [3]. EMPs phenotyped as CD31+/CD41−, and CD144+ 
are also elevated levels in VAD-patients [3].
Additional to the MPs of specific lineages described above—erythrocytes, leukocyte, platelet 
and endothelial—PS-expressing MPs of unknown lineage have been suggested as a potential 
biomarker of adverse events in VAD-patients implanted with a HeartMate II [2]. Patients who 
developed an adverse event, including ventricular tachycardia storm, non-ST elevation myo-
cardial infarction, arterial thrombosis, gastrointestinal bleeding, and stroke had significantly 
higher levels of PS+ MPs than patients with no adverse events [2].
2.2. Pre-clinical in vivo haemocompatibility of blood-handling devices
The flow cytometry data from published pre-clinical in vivo studies of LVADs is focussed 
mainly on platelets with the exception of one study on leukocytes. There is no published data 
on erythrocytes.
2.2.1. Leukocytes
Snyder et al. have published the only in vivo leukocyte work wherein the aim was to develop 
assays for leukocyte-platelet aggregates and monocyte tissue factor expression [21]. Using 
an anti-bovine granulocyte antibody (CH138A) or anti-CD14 (TüK4) in combination with 
antibody CAPP2A (anti-ruminant CD41/61), calves implanted with CF-LVADs (HeartMate II 
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or EVAHEART) had significantly elevated levels of both neutrophil-platelet and monocyte-
platelet aggregates compared to pre-operative [21]. Monocyte tissue factor expression moni-
tored using an anti-bovine tissue factor antibody developed by Stephen Carson at University 
of Nebraska [22], also showed a dramatic increase immediately post-operatively and signifi-
cantly elevated levels throughout the 30-day study [21].
2.2.2. Platelets
Bovine platelet activation and microaggregates have been studied using various markers 
in calves implanted with CF-VADs. Baker et al. developed a method using the antibod-
ies BAQ56, BAQ125 and GC5A (platelet antigen, CD equivalent unknown, available from 
Washington State University) to measure platelet activation, and CAPP2A (anti-CD41/CD61) 
to measure platelet microaggregates in calves implanted with CF-LVADS (the Sun Medical 
centrifugal pump or the HeartMate II) [23]. Platelet microaggregates, i.e. platelet positive 
events (binding anti-bovine CD41/61 antibody) with forward scatter larger than single plate-
lets, increased post-operatively and then showed some decline in calves implanted with Sun 
Medical whereas they remained elevated in the calves implanted with HeartMate II. Platelet 
activation increased post-operatively for both implants and remained elevated. BAQ56 pro-
vided the strongest signal and GC5 the weakest signal of the three antibodies, but BAQ125 
and GC5 exhibited the strongest agreement with one another, and with the circulating micro-
aggregates [23].
Snyder et al. used a modified version of Baker’s methodology in two studies of calves implanted 
with the CF-LVADs—HeartMate II [24] and the EVAHEART [25]. Snyder showed that the 
microaggregate levels in surgical sham controls remained at pre-operative levels, confirming 
that the CF-LVAD and not the cardiac surgery cause elevated levels [24]. Microaggregate lev-
els increased post-implantation, and decreased within the first week in all animals implanted 
with the EVAHEART [25], and in those animals implanted with the HeartMate II who had an 
uneventful post-operative course [24]. In calves who suffered adherent thrombi in the outflow 
region of the pumps, the microaggregate levels either remained elevated or increased before 
conclusion of the study [24].
Part of Snyder’s modification was the inclusion of additional markers for platelet activation 
to address the limitations BAQ56, BAQ125, and GC5 with their unknown target antigens, 
namely Annexin V binding [24], anti-CD62P and anti-CD63 [25]. All platelet activation/apop-
tosis markers tested (BAQ125, GC5, Annexin V, CD62P, CD63) increased immediately after 
implantation and remained significantly elevated in CF-LVAD animals versus the pre-operative 
control [24, 25]. Those tested in sham animals (BAQ125, GC5, Annexin-V) decreased around 
2 weeks post-operatively [24]. Although CD62P and CD63 successfully identified activated 
platelets in CF-LVAD calves, the signal was weaker than that of the BAQ125 and GC5 anti-
bodies [25].
CAPP2A also binds to ovine platelets whereas anti-bovine platelet activation antibodies 
BAQ125 and GC5 do not. Hence, Johnson et al. used CAPP2A as a platelet lineage marker 
along with cross-reactive anti-human CD62P antibodies (clones Psel.KO.2.7 and Psel.KO.2.12) 
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to assess platelet activation in sheep implanted with paediatric CF-LVADs [26–28]. Johnson 
showed that, similarly to calves, platelet activation increases post-operatively in surgical 
sham control sheep and returns to pre-operative levels at around 2 weeks. The implanted 
sheep did not demonstrate a common pattern [28]. However, a finding also consistent with 
previous work was that platelet activation spiked in animals that suffered complications 
[26–28].
2.3. In vitro haemocompatibility of blood-handling devices
Similarly to the in vivo studies, the in vitro studies of VADs using flow cytometry are focussed 
on platelets, with some recent studies introducing leukocyte data. There is no published data 
on erythrocytes.
2.3.1. Leukocytes
Work from our group has shown that bovine leukocytes shed microparticles, measured as 
increasing levels of CD45+ MPs (Figure 1), during in vitro pumping in the extracorporeal 
CF-LVADs CentriMag and RotaFlow, and the intracorporeal CF-LVAD VentrAssist [29, 30]. 
We have also shown that CD45+ MPs increase significantly when sheep rather than bovine 
blood was pumped with the CentriMag [31]. Subtypes of leukocyte MPs were discovered 
Figure 1. Flow plots showing bovine and ovine blood pumped through the CentriMag. Whole blood was collected into 
CPDA-1 anticoagulant primed with antibiotics/antimycotics and gentamicin. Blood was diluted with PBS to achieve a 
haematocrit of 30±2% according to ASTM standards and entered into the mock circulatory loop. The CentriMag was 
operated at a speed of 2200 rpm, flow of 5 L/min, and pressure 100 mmHg for both species. Samples were removed every 
2 h and stained with CD45-PE and 7AAD. CD45+ events were gated on a SSC vs. 7AAD plot and events with a low SSC 
were identified as leukocyte-derived microparticles (MPs).
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in sheep blood during in vitro VAD testing using antibodies cross-reactive with human and 
bovine blood. The main subtypes were CD11bbright/HLA-DR− and CD11bdim/HLA-DR+, dis-
covered using a four-colour panel (Figure 2), and we suggested that these are derived from 
granulocytes and lymphocytes, respectively [31].
2.3.2. Platelets
The first flow cytometry assessments of platelet activation and microaggregates during in 
vitro testing in CF-LVADs was carried out by Johnson C et al. using sheep blood. Activation 
was assessed using CAPP2A as a lineage marker and anti-CD62P (clone Psel.KO.2.7), and 
was found to increase throughout the duration of the test of the PediaFlow [28]. We have 
used CAPP2A, BAQ125, and Annexin V to assess platelet activation in bovine blood in the 
CentriMag, but did not find any significant activation. However, the CentriMag has a mag-
netically levitated impeller, resulting in minimal heat, and also large gaps minimising blood 
damage, so these findings were not surprising [30] (Figure 3).
Figure 2. Flow plots showing ovine blood pumped through the CentriMag operated at a speed of 2200 rpm, flow of 
5 L/min, and pressure 100 mmHg. Whole blood was collected into CPDA-1 anticoagulant primed with antibiotics/
antimycotics and gentamicin. Blood was diluted with PBS to achieve a haematocrit of 30±2% according to ASTM 
standards and entered into the mock circulatory loop. Samples were stained with CD11b-FITC and HLA-DR-PC7. 
Events with a low SSC and positive for these markers were gated as CD11b or HLA-DR positive microparticles (MPs).
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3. Future possibilities for device developers
Although flow cytometry has been used clinically to study phenotype, activation status and 
MPs of the main circulating cell types in patients implanted with mechanical circulatory sup-
port devices, the use of flow cytometry for pre-clinical in vivo and in vitro studies has been 
very limited. As can be seen in Table 1, there are many potential gaps that could be filled by 
developing assays for in vitro use, as well as in vitro assays to translate to the pre-clinical and 
clinical in vivo setting. The in vitro setting will always provide the worst case scenario, as the 
pumped blood volume is 10 times less than in the VAD-patient and the blood components are 
therefore experiencing an increased amount of pumping, not to mention experiencing plastic 
tubing instead of endothelial coated vasculature. In addition, there is no supply of oxygen or 
nutrients other than what is already present in the plasma, and there is no efficient removal of 
waste products or damage/dead cells. Cells are therefore more vulnerable in vitro. Therefore, 
if a VAD induces detectable cellular damage clinically, it will most certainly be measurable in 
Figure 3. Flow plots showing bovine blood pumped through the CentriMag operated at a speed of 2200 rpm, flow 
of 5 L/min, and pressure 100 mmHg. Whole blood was collected into CPDA-1 anticoagulant primed with antibiotics/
antimycotics and gentamicin. Blood was diluted with PBS to achieve a haematocrit of 30±2% according to ASTM 
standards and entered into the mock circulatory loop. Samples were stained with CAPP2A-PE, a marker for resting 
platelets. Forward and side scatter plots were used to identify platelets. CAPP2A negative platelet events were identified 
as activated platelets (Act Plt).
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an in vitro test. Platelet activation is so far the only assay that has been fully reverse-translated 
from bedside to bench, but there is no reason to believe that it should not be possible to create 
suitable flow cytometry assays for erythrocytes and leukocytes for all stages in the product 
development process. The benefits of implementing such assays for the devices in develop-
ment could be identification of designs with minimal impact on blood components, and thus 
a reduction of the blood-damage related life-threatening complications so commonly seen in 
VAD-patients including bleeding, stroke, device thrombosis and infection.
3.1. Erythrocytes
The VADs in current use are designed to minimise high shears to blood for prolonged dura-
tions to avoid haemolysis. However, erythrocytes demonstrate impaired capacity to deform 
when exposed to shear stress well below the “haemolytic threshold” [32]. Thus, there is a 
need for assays that can pick up more subtle damage to erythrocytes. We propose that quan-
tifying RBC MPs as a possible means of assessing sub-haemolytic damage should be investi-
gated to see whether or not it can fill this need.
Cell type Assay In vitro In vivo Clinical
Ovine Bovine Ovine Bovine
Erythrocytes CD235+ MPs ✓
Leukocytes CD45+ MPs ✓ ✓ ✓
Granulocytes CD11b + MPs ✓ ✓
CD11b + expression ✓
Monocytes TF expression ✓ ✓
Lymphocytes Subset levels: CD4+, CD8+, CD4+/
CD25+
✓
ROS, apoptosis ✓
HLA-DR+ MPs ✓
Platelets Activation ✓ ✓ ✓ ✓ ✓
Phosphatidylserine ✓ ✓ ✓
MPs ✓
ROS, etc. ✓
Microaggregates ✓ ✓
GRA-PLT Microaggregates ✓ ✓
MON-PLT Microaggregates ✓ ✓
Unknown Phosphatidylserine MPs ✓
Table 1. Gap analysis of assays for evaluating blood-handling devices.
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3.2. Leukocytes
Activated CD15+CD11b+ neutrophils, have been detected in VAD-patients and clinical data 
shows that the activation status might influence the patient’s susceptibility to infection [5]. 
With additional evidence that CD11b+ MPs are increased in VAD-patients, and generated dur-
ing in vitro pumping in ovine blood, it makes sense to propose further investigations into its 
utility as a stratifier to identify those at the highest risk of developing infections in order to 
offer prophylaxis, thereby reducing infection rates.
VAD-related increases in monocytes expressing TF have been demonstrated both clinically 
[10, 11] and in vivo [21]. CD14+/TF+ MPs are elevated in primates, healthy volunteers, and 
patients subjected to infectious stimuli that could result in disseminated intravascular coag-
ulation [33]. Thus, we propose that in VAD-patients with ongoing driveline infections, the 
presence of CD14+/TF+ monocytes/MPs potentially could identify those patients at risk for 
a thrombotic event in order to offer prophylaxis. Assays could also be developed for in vitro 
testing of devices to see if the combination of design, foreign material and/or shear stress in 
different device models results in TF-expression. However, care should be taken when assess-
ing CD14+TF+ MPs as false positive results can be generated by the antibody preparations 
used [34].
The lack of pulsatility has been suggested as a factor that could be contributing to the com-
plications related to aortic valve insufficiency, gastrointestinal bleeding, stroke, pump throm-
bosis, and haemolysis [35]. A link between pulsatility and blood damage has so far only been 
described for the blood coagulation protein von Willebrand Factor (vWF), which appears to 
degrade more in patients with pulsatile compared to non-pulsatile VADs [36]. As our group 
has shown, vWF degradation caused by shear stress in vitro can be assessed using flow cytom-
etry a flow cytometry-based ristocetin assay [37]. However, it appears as if T cells could be 
another missing link needed to describe the effects of non-pulsatile [13] and pulsatile [14, 15] 
flow on the blood. Therefore, we propose that assays for T-cells are established for sheep and 
cow blood in order to study the effects of pulsatility, in order to gather more scientific evi-
dence that could be used to interpret the clinical data.
Other leukocyte subsets of interest to develop methods for studying would be B-cells. 
Schuster et al. described that the T-cell apoptosis observed in patients with pulsatile VADs, 
was induced by a B-cell response to polyurethane, a material commonly used for the mem-
branes in pulsatile devices [38, 39]. Continuous flow devices are typically made from metals 
and ceramics, and do not contain polyurethane. Hence, pulsatility studies should be made in 
combination with various biomaterial controls, including for example titanium alloys com-
monly used in VADs [40, 41].
3.3. Platelets
In vitro and in vivo platelet studies have so far been limited to studying activation by increased 
expression of platelet markers, but the expression of platelet activation surface markers has so 
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far failed to be linked to clinically relevant events. However, Mondal’s portfolio of potential 
risk stratifying platelet parameters [18–20] are of importance to study in vitro. Hence, we pro-
pose that effort be made to translate Mondal’s methods to bovine and/or sheep blood for in 
vitro studies of platelet reactive oxygen species, mitochondrial damage, and α2bβ3 expression 
to investigate any potential links between device design and its influence on platelet health. 
Since platelets are numerous in blood, very small volumes can be used to analyse them. In 
combination with a multidimensional approach to assess several parameters simultaneously, 
it would be a very attractive addition to the care pathway for patients with heart failure pre- 
and post-VAD implantation.
3.4. Cytokines
Cytokines have not been assessed using flow cytometry in a VAD-setting, but recent clinical 
data on TNFα-levels in VAD-patients might spur a change. High levels of TNF-α were associ-
ated with increased risk of bleeding complications in patients with CF-VADs (HeartMate II or 
HVAD) [42]. Measurement of TNF-α by flow cytometry in whole blood would offer a much 
more rapid method, a lower sample volume required, and could be combined with other cel-
lular markers of interest into a multidimensional approach [43].
3.4.1. Overcoming practical hurdles
A reason for hesitating in this approach might be the limited availability of reagents for ani-
mal blood. However, progress has been made recently in this field by exploiting the cross-
reactivity of some antibody clones. We identified the utility of an antibody clone targeting 
CD62P, clone Psel.KO.2.5, that could measure shear-induced platelet activation in human, 
bovine, ovine, and porcine blood [44]. Johnson et al. also made significant contributions in 
identifying cross-reactive platelet antibodies against bovine and ovine platelets [45]. We have 
used antibodies cross-reactive against bovine and human targets in developing a multico-
lour flow cytometry panel for sheep leukocyte MPs released during in vitro VAD-pumping. 
This panel should offer translation to both the pre-clinical in vivo and clinical setting [31]. To 
address the cost of antibodies and reduce the need for additional haematology analysers, 
we have also demonstrated that flow cytometry in combination with DNA dyes and count-
ing beads could be used to assess complete leukocyte counts and viability in bovine, ovine, 
and human blood [46]. Although personal flow cytometers have been introduced lately, they 
are still not widespread and many investigators rely on the use of core facilities for flow 
cytometry acquisition and analysis. Where the animal lab is not in close proximity to the flow 
cytometry core facility there may be a need to preserve the animal blood prior to shipping for 
analysis. CytoChex and Streck stabilising fluid were developed to address the need to pre-
serve CD4 antigens for HIV drug trials in remote locations for central analysis during clinical 
trials, but have now been shown to stabilise several human leukocyte antigens [47–49]. We 
are developing protocols for the use of these reagents with bovine and ovine blood to stabilise 
samples for several days and enable subsequent flow cytometry analysis of platelet and leu-
kocyte parameters (in submission).
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4. Conclusion
Assessment of red blood cell damage through measurement of plasma free haemoglobin is a 
key assay required by regulatory bodies in the development of new blood-handling devices. 
However, more sophisticated flow cytometry screening methods that enable evaluation of a 
wider array of blood cell types and blood borne proteins could be used in combination with 
other design tools to inform iterative design improvements. Such an approach would enable 
device developers to progress new designs that have minimal total blood trauma, and ulti-
mately put safer devices on the market. The use of multiparametric flow cytometry in the 
design cycle and clinical use of medical devices that contact blood is in its infancy. Clearly, 
there are many advantages to such an approach. The key advantage is the ability to analyse 
the phenotype of multiple haematopoietic cell populations simultaneously in small volumes 
of blood. Such methodology would enable the same analysis protocols to be used at all stages 
of design and implementation: in vitro studies, pre-clinical studies in different animal spe-
cies, and then in clinical studies once devices are implanted in humans. Multiparametric flow 
cytometry also enables the incorporation of functional outputs such as cell viability, apoptosis, 
reactive oxygen species (ROS) production and cytokine production. These are critical if the 
impact of device-associated biomaterials and shear stress on haematopoietic cells is to be deter-
mined; there might not be phenotypic changes but cell function might be affected dramatically. 
The main challenges to implementing multiparametric flow cytometry in this setting relate 
to the availability of reagents that are truly multi-species and enable a single methodological 
approach to be used across the device development life cycle. This is more challenging when it 
comes to cell phenotyping that typically requires antibodies to specific cell surface markers but 
easier to implement for functional assays related to cell viability/apoptosis and measures such 
as ROS. Other challenges relate to flow cytometer availability to the research and development 
team as that will dictate fluorochrome choice and assay design. Also, data analysis becomes 
demanding as the number of parameters studied simultaneously increases and machine learn-
ing approaches need to be developed alongside development of multiparameter strategies. 
Rapid advances in fluorochrome technology and the development of mass cytometry facilitate 
a multiparametric approach but there remain limitations in fluorochrome choices for reagents 
targeting surface markers and cytokines of cells from animal species such as cows, pigs and 
sheep. Demand for these reagents will drive their availability but this demand will only occur 
if the device development community adopt standardised approaches. Underpinning this 
would be a requirement from regulatory bodies for flow cytometry-based analysis of cell health 
and function as part of the development and evaluation of blood handling medical devices.
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